JP2023522907A - 抗ｃｃｌ２４抗体を使用する処置方法 - Google Patents

抗ｃｃｌ２４抗体を使用する処置方法 Download PDF

Info

Publication number
JP2023522907A
JP2023522907A JP2022563379A JP2022563379A JP2023522907A JP 2023522907 A JP2023522907 A JP 2023522907A JP 2022563379 A JP2022563379 A JP 2022563379A JP 2022563379 A JP2022563379 A JP 2022563379A JP 2023522907 A JP2023522907 A JP 2023522907A
Authority
JP
Japan
Prior art keywords
ccl24
monoclonal antibody
pharmaceutical composition
administration
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022563379A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522907A5 (enExample
Inventor
モル，アディ
アハロン，アーノン
ハシュムエリ，シャロン
サルト，ミハル セガール
バラシ，ネタ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemomab Ltd
Original Assignee
Chemomab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemomab Ltd filed Critical Chemomab Ltd
Publication of JP2023522907A publication Critical patent/JP2023522907A/ja
Publication of JP2023522907A5 publication Critical patent/JP2023522907A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2022563379A 2020-04-22 2021-04-20 抗ｃｃｌ２４抗体を使用する処置方法 Pending JP2023522907A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013793P 2020-04-22 2020-04-22
US63/013,793 2020-04-22
PCT/IL2021/050447 WO2021214759A1 (en) 2020-04-22 2021-04-20 Method of treatment using anti-ccl24 antibody

Publications (2)

Publication Number Publication Date
JP2023522907A true JP2023522907A (ja) 2023-06-01
JP2023522907A5 JP2023522907A5 (enExample) 2024-04-11

Family

ID=75787181

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022563379A Pending JP2023522907A (ja) 2020-04-22 2021-04-20 抗ｃｃｌ２４抗体を使用する処置方法

Country Status (9)

Country Link
US (1) US20230235037A1 (enExample)
EP (1) EP4139352A1 (enExample)
JP (1) JP2023522907A (enExample)
KR (1) KR20230013037A (enExample)
CN (1) CN115427445A (enExample)
AU (1) AU2021259682A1 (enExample)
CA (1) CA3172627A1 (enExample)
IL (1) IL296579A (enExample)
WO (1) WO2021214759A1 (enExample)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004055164A2 (en) * 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JP2017508461A (ja) * 2014-03-04 2017-03-30 ケモマブ リミテッドＣｈｅｍｏｍＡｂ Ｌｔｄ． さらなるｃｃｒ３−結合ケモカインを認識する抗エオタキシン−２抗体
JP2019509311A (ja) * 2016-03-25 2019-04-04 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子の製剤
JP2020511439A (ja) * 2017-03-08 2020-04-16 ケモマブ リミテッドＣｈｅｍｏｍＡｂ Ｌｔｄ． 肝臓病の処置における使用のための抗ｃｃｌ２４（エオタキシン２）抗体

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121022A (en) * 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
EP1706424B1 (en) * 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
US9067989B2 (en) 2009-01-28 2015-06-30 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders
EP2490026A4 (en) * 2009-10-16 2013-08-21 Mochida Pharm Co Ltd MARKER ASSOCIATED WITH NON ALCOHOLIC STÉATOHÉPATITE
BR112012022223B1 (pt) * 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma
CR20170060A (es) * 2014-08-19 2017-04-18 Merck Sharp & Dohme Anticuerpos anti tigit
WO2016040882A1 (en) * 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
US20180008707A1 (en) * 2015-02-13 2018-01-11 Sanofi Stable liquid formulation for monoclonal antibodies
EP4652926A3 (en) * 2016-10-12 2026-03-18 Bioverativ USA Inc. Anti-c1s antibodies and methods of use thereof
CN107198773A (zh) * 2017-06-08 2017-09-26 上海药明生物技术有限公司 重组抗pd‑l1全人单克隆抗体的液体制剂
EP3660155A4 (en) * 2017-07-27 2021-04-07 Daiichi Sankyo Company, Limited ANTI-CD147 ANTIBODY
CN109745559A (zh) * 2017-11-01 2019-05-14 三生国健药业（上海）股份有限公司 抗人il-17a的单克隆抗体的液体制剂
CN110354073B (zh) * 2018-04-09 2021-10-01 鲁南制药集团股份有限公司 一种免疫抑制剂单克隆抗体的液体制剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004055164A2 (en) * 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JP2017508461A (ja) * 2014-03-04 2017-03-30 ケモマブ リミテッドＣｈｅｍｏｍＡｂ Ｌｔｄ． さらなるｃｃｒ３−結合ケモカインを認識する抗エオタキシン−２抗体
JP2019509311A (ja) * 2016-03-25 2019-04-04 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子の製剤
JP2020511439A (ja) * 2017-03-08 2020-04-16 ケモマブ リミテッドＣｈｅｍｏｍＡｂ Ｌｔｄ． 肝臓病の処置における使用のための抗ｃｃｌ２４（エオタキシン２）抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BEN-ARI Z. ET AL.,: ""CM-101 a novel CCL24 blocking monoclonal antibody ameliorates hepatic injury in NASH induced mouse", AASLD ANNUAL MEETING 2017, JPN6025012105, 2017, ISSN: 0005557992 *
SEGAL-SALTO M. ET AL., JHEP REPORTS, vol. 2, JPN6025012104, 2 January 2020 (2020-01-02), pages 100064, ISSN: 0005557991 *

Also Published As

Publication number Publication date
EP4139352A1 (en) 2023-03-01
IL296579A (en) 2022-11-01
WO2021214759A1 (en) 2021-10-28
KR20230013037A (ko) 2023-01-26
CA3172627A1 (en) 2021-10-28
US20230235037A1 (en) 2023-07-27
AU2021259682A1 (en) 2022-10-20
CN115427445A (zh) 2022-12-02

Similar Documents

Publication Publication Date Title
JP7579227B2 (ja) 瘻孔を伴うクローン病の治療用ベドリズマブ
JP2018158934A (ja) 抗ｉｌ−５抗体を投与するための方法
ES2926700T3 (es) Anticuerpos anti Eotaxina-2 que reconocen quimiocinas de unión a CCR3 adicionales
JP7375252B2 (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
US20250011416A1 (en) Methods for the treatment of cardiovascular disease
JP2018533588A (ja) 治療パラダイム
JP7798763B2 (ja) Ｃ５関連疾患の治療または予防のための投与レジメン
KR20220064998A (ko) 콜레스테롤 관련 질환을 예방하거나 치료하기 위한 방법에 있어서 항 pcsk9 항체의 용도
RU2832323C1 (ru) Способ лечения с использованием антитела против CCL24
US20230235037A1 (en) Method of treatment using anti-ccl24 antibody
JP2023011819A (ja) 化膿性汗腺炎の治療のための汎ｅｌｒ＋ｃｘｃケモカイン抗体
US20250326831A1 (en) Methods for treating disease using psmp antagonists
RU2822134C2 (ru) Лечение поражений кожи и зуда у пациентов с узловатой почесухой
WO2026072994A1 (en) Methods for the treatment of cardiovascular disease
WO2025072725A1 (en) Methods for the treatment of cardiovascular disease
CN121889429A (zh) 用于治疗嗜酸性肉芽肿性多血管炎的IL-5R-α抗体
JP2025131673A (ja) 心血管疾患の治療用の内皮リパーゼ抗体
WO2025006989A2 (en) Methods for detection and treatment of cancer
CN114746444A (zh) 使用白介素-17(il-17)拮抗剂治疗扁平苔藓的方法
NZ744721A (en) Treatment for rheumatoid arthritis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250625

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250909